covalent immunoproteasome inhibitor

subcutaneous agent in Ph. I/II for SLE and LN

designed from proteasome inhibitors

Drug Metabolism and Disposition

Kezar Life Sciences, San Francisco, US

Chemical structure of KZR-616 Kezar Life Sciences covalent immunoproteasome inhibitor

The Kezar Life Sciences covalent immunoproteasome inhibitor, KZR-616, licensed from Onyx, targets the LMP7 and LMP2 active sites of the immunoproteasome, and is currently in Ph. II trials for autoimmune disorders…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: